VIATRIS INC. Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
VIATRIS INC. (VTRS) reported Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations of $19.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations · last filed 2026-02-26
- VIATRIS INC. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2025 was $19.00M, a 41.79% increase from fiscal 2024.
- VIATRIS INC. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2024 was $13.40M, a 3.08% increase from fiscal 2023.
- VIATRIS INC. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2023 was $13.00M, a 584.21% increase from fiscal 2022.
- VIATRIS INC. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2022 was $1.90M, a 72.86% decline from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month as first filed |
|---|---|---|
| 2025-12-31 | $19.00M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $13.40M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $13.00M 10-K · filed 2026-02-26 | |
| 2022-12-31 | $1.90M 10-K · filed 2025-02-27 | |
| 2021-12-31 | $7.00M 10-K · filed 2024-02-28 | |
| 2020-12-31 | $7.00M 10-K · filed 2023-02-27 | $0.00 10-K · filed 2021-03-01 |
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 | |
| 2018-12-31 | $0.00 10-K · filed 2023-02-27 | $34.90M 10-K · filed 2021-03-01 |
| 2017-12-31 | $34.90M 10-K · filed 2022-02-28 | |
| 2016-12-31 | $70.70M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |